Literature DB >> 2401755

Chemical and biological studies of a cigarette that heats rather than burns tobacco.

J D deBethizy1, M F Borgerding, D J Doolittle, J H Robinson, K T McManus, C A Rahn, R A Davis, G T Burger, J R Hayes, J H Reynolds.   

Abstract

Cigarettes can be developed that heat rather than burn tobacco. Such products would be expected to have less "tar" and other combustion products than cigarettes that burn tobacco. With one product of this type, benzo(a)pyrene, N-nitrosamines, phenolic compounds, acetaldehyde, acrolein, hydrogen cyanide, and N-heterocyclic compounds have been reduced 10- to 100-fold compared to the Kentucky reference (1R4F) cigarette, a representative low-tar cigarette. The yields of nicotine and carbon monoxide from this new cigarette are less than the yields of 95% and 75%, respectively, of the cigarettes sold in the United States during 1988. Nicotine absorption from smoking this new cigarette is not significantly different from that of tobacco-burning cigarettes yielding equivalent levels of nicotine. The urine mutagenicity of smokers of new cigarettes is significantly less (P less than .05) than that of smokers of tobacco-burning cigarettes and is not significantly different (P greater than .10) from that of nonsmokers. We conclude that cigarettes which heat rather than burn tobacco can reduce the yield of tobacco combustion products. This simplification of smoke chemistry had no effect on nicotine absorption in smokers and resulted in a reduction of biological activity in smokers as measured by urine mutagenicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401755     DOI: 10.1002/j.1552-4604.1990.tb03639.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Biomarkers of Chronic Acrolein Inhalation Exposure in Mice: Implications for Tobacco Product-Induced Toxicity.

Authors:  Daniel J Conklin; Marina V Malovichko; Iris Zeller; Trinath P Das; Tatiana V Krivokhizhina; Blake H Lynch; Pawel Lorkiewicz; Abhinav Agarwal; Nalinie Wickramasinghe; Petra Haberzettl; Srinivas D Sithu; Jasmit Shah; Timothy E O'Toole; Shesh N Rai; Aruni Bhatnagar; Sanjay Srivastava
Journal:  Toxicol Sci       Date:  2017-08-01       Impact factor: 4.849

2.  Glycerol particle cigarettes: a less harmful option for chronic smokers.

Authors:  G Sutherland; M A Russell; J A Stapleton; C Feyerabend
Journal:  Thorax       Date:  1993-04       Impact factor: 9.139

3.  Electronic cigarette-generated aldehydes: The contribution of e-liquid components to their formation and the use of urinary aldehyde metabolites as biomarkers of exposure.

Authors:  Daniel J Conklin; Mumiye A Ogunwale; Yizheng Chen; Whitney S Theis; Michael H Nantz; Xiao-An Fu; Lung-Chi Chen; Daniel W Riggs; Pawel Lorkiewicz; Aruni Bhatnagar; Sanjay Srivastava
Journal:  Aerosol Sci Technol       Date:  2018-08-23       Impact factor: 2.908

4.  Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit.

Authors:  K O Fagerström; J R Hughes; T Rasmussen; P W Callas
Journal:  Tob Control       Date:  2000-09       Impact factor: 7.552

Review 5.  Potential reduced exposure products (PREPs) in industry trial testimony.

Authors:  Geoffrey Ferris Wayne
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

Review 6.  Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Authors:  Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

7.  Invisible smoke: third-party endorsement and the resurrection of heat-not-burn tobacco products.

Authors:  Jesse Elias; Pamela M Ling
Journal:  Tob Control       Date:  2018-06-06       Impact factor: 7.552

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.